European urology
Re: Final Overall Survival and Safety Analyses of the Phase III PSMAfore Trial of [177Lu]Lu-PSMA-617 Versus Change of Androgen Receptor Pathway Inhibitor in Taxane-Naive Patients with Metastatic Castration-Resistant Prostate Cancer.
Pedro C Barata, Abby L Grier
Published: 202510.1016/j.eururo.2025.12.005
No abstract available for this study.